FDA approves diabetes drug that also helps with weight loss

This photo provided by Novo Nordisk shows an injection pen of the company's drug Ozempic. On Tuesday, Dec. 5, 2017, the Food and Drug Administration approved the new, long-acting diabetes drug that reduces blood sugar levels and also helps people lose significant weight. (Novo Nordisk via AP)

TRENTON, N.J. — U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.

Danish drugmaker Novo Nordisk said the Food and Drug Administration approved its once-a-week shot for people with Type 2 diabetes. The drug, Ozempic, also known as semaglutide, works by stimulating the body's own insulin production and reducing appetite.

In one big company-funded study, Ozempic, on average, reduced long-term blood sugar levels at least 2 ½ times as much as a popular daily diabetes pill, Merck & Co.'s Januvia. It also helped study participants lose two to three times as much weight as those in the comparison group.

Over 56 weeks, patients who got a lower dose of Ozempic lost an average of 9.5 pounds (4.3 kilograms) while those who got a higher dose lost 13.5 pounds (6.1 kilograms). The patients who took Januvia lost an average of 4 pounds (1.9 kilograms).

The 1,200 study participants were also taking one or two standard diabetes medicines.

Novo Nordisk, a leader in diabetes care, has also been testing the drug separately for weight loss alone.

Many Type 2 diabetes patients are overweight or obese, and losing significant weight usually helps them reduce their blood sugar and better control their diabetes. Over time, too high sugar in the blood can damage multiple organs and weaken circulation.

The new drug comes in injector pens and costs about the same as similar weekly drugs: $676 for a four- to six-week supply without insurance. Novo Nordisk already sells a similar once-a-day shot, Victoza.

Ozempic will compete with other popular once-a-week drugs in the same class, including Eli Lilly and Co.'s Trulicity and AstraZeneca PLC's Bydureon, which don't produce as much weight loss. However, they all carry warnings about possible serious side effects, including kidney damage and inflammation of the pancreas. They also may be linked to thyroid cancer, so people taking all drugs in the class are being followed via a patient registry.

Januvia is in a different drug class.

___

Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma

Must Read

25 congressional members question plant-based...

Dec 23, 2016

Twenty-five bipartisan members of Congress say if it's from soybeans, almond or rice, it should not...

Massive WWII bomb is defused in German town of...

Dec 25, 2016

Explosives experts have defused a large World War II aerial bomb in the southern German city of...

Winter storm weakens but travel still hazardous...

Dec 27, 2016

The fury of the winter storm that swept into the northern Great Plains on Christmas Day was...

AP New Year's poll: Americans hopeful for a...

Dec 26, 2016

A poll finds that Americans are hopeful that things are going to get better for the country in 2017...

What drops on New Year's Eve? Not just Times...

Dec 27, 2016

That glittering ball in Times Square may be the best-known object dropping on New Year's Eve, but...

People also read these

Australian Parliament gets bill to set up gay...

Sep 14, 2016

Australia's prime minister has introduced legislation to Parliament to allow a public but...

Trump campaign pushes food safety rollbacks, then...

Sep 15, 2016

A fact sheet issued by Donald Trump's campaign on Thursday said he would roll back food safety...

Trump campaign pitches _ then deletes _ food...

Sep 16, 2016

Trump campaign pitched food safety regulatory rollback but later deleted it from website

Mall fights send post-holiday shoppers scrambling...

Dec 27, 2016

Fights have broken out at malls around the country, sending post-holiday shoppers scrambling for...

Winter storm weakens but thousands still without...

Dec 27, 2016

The furious winter storm that swept into the northern Great Plains on Christmas Day has weakened...

About Us

The World Insiders brings you exclusive coverage from across the globe in a timely, easy to consume format sourced directly from our regional media partners.

Contact us: sales@theworldinsiders.com

Subscribe Now!